{
}
Akero Therapeutics, focused on treatments for metabolic diseases, has seen significant institutional investment, with several firms increasing their stakes in the company. UBS Group raised its price target for Akero from $42 to $109, indicating a potential upside of over 103%. Despite a recent earnings miss, the stock maintains a "Buy" rating from multiple analysts, with a consensus target price of $75.86. Insider trading activity includes notable sales by executives, reflecting a decrease in their ownership stakes.
UBS has raised its price target on Akero Therapeutics to $109 from $42 while maintaining a Buy rating. The clinical-stage company is focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH), with its lead candidate, Efruxifermin (EFX), currently undergoing multiple phase IIb and phase III studies. EFX, an analog of fibroblast growth factor 21, aims to provide convenient once-weekly dosing for patients.
Novo Nordisk plans to seek regulatory approval for semaglutide as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) after positive Phase 3 trial results. The study showed significant improvements in liver scarring and resolution of MASH among patients receiving semaglutide compared to placebo. Despite the promising findings, analysts remain cautious about its competitive edge in the MASH treatment landscape.
Akero Therapeutics, Inc.
Companies
| Symbol | AKRO |
| Name | Akero Therapeutics, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | CA |
| City | South San Francisco |
| Zipcode | 94080 |
| Website | http://www.akerotx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
akero therapeutics sees increased institutional investment and positive analyst ratings
Victory Capital Management Inc.
UBS Group AG
Mirae Asset Global Investments Co. Ltd. - Mirae Asset Tiger Global Artificial Intelligence & Robotic
Eastern Bankshares, Inc.
Morgan Stanley
Point72 Asia (Singapore) PTE. Ltd.
Akero Therapeutics, Inc.
Bank of America Corporation
Canaccord Genuity Group Inc.
Citigroup Inc.
USA
William Richard White
Show more
20:31 01.02.2025
ubs raises akero therapeutics price target to 109 maintains buy rating
17:24 31.01.2025
novo seeks approval for semaglutide as treatment for liver disease
United States Dollar
Eli Lilly and Company
Akero Therapeutics, Inc.
Novo Nordisk A/S
Zealand Pharma A/S
Intercept Pharmaceuticals Inc.
Madrigal Pharmaceuticals, Inc.
Boehringer Ingelheim KG
89bio, Inc.
DNK
Thomas Smith
Andy Hsieh
Brian Abrahams
Martin Holst Lange
William Blair
Show more
15:45 01.11.2024
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Central Bank Actions
Industry Mergers & Acquisitions
Banking Regulations
CEO Changes
Startups & Entrepreneurship
Market Analysis and Predictions
Financial Scams and Security
Supply Chain Management
Workplace Trends
Government Economic Policies
AI Innovations
Energy Sector Developments
Cryptocurrency Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Barclays PLC
Wells Fargo & Company
Alphabet Inc.
Tesla, Inc.
Citigroup Inc.
Lloyds Banking Group plc
Deutsche Bank RV Global PP
PepsiCo, Inc.
Commerzbank AG
Google Inc.
NatWest Group plc
BNP Paribas SA
Morgan Stanley
UBS Group AG
JPMorgan Chase & Co.
NVIDIA Corporation
Amazon.com, Inc.
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People: